This article explores the transformative role of chemical genetic interactions in accelerating drug discovery, with a focus on yeast and parasite models.
The escalating global health crisis of antimicrobial resistance necessitates the discovery of novel therapeutic agents.
This article provides a comprehensive analysis of the evolutionary conservation of drug targets across diverse eukaryotic species, a critical consideration for modern drug discovery.
This article provides a comprehensive overview of comparative chemical genomics, an integrative approach that combines large-scale genetic perturbations with chemical screening to elucidate drug mechanisms of action (MoA).
This article provides a comprehensive overview of chemical genomic profiling as a powerful, unbiased approach for target deconvolution in phenotypic drug discovery.
This article provides a comprehensive framework for researchers and drug development professionals selecting between Next-Generation Sequencing (NGS) and Sanger sequencing to validate chemogenomic screening results.
This article provides a comprehensive comparison of genomic DNA (gDNA) and cell-free DNA (cfDNA) based Next-Generation Sequencing (NGS) methodologies within chemogenomic studies.
This article provides researchers, scientists, and drug development professionals with a comprehensive framework for selecting and optimizing next-generation sequencing (NGS) library preparation kits specifically for chemogenomics applications.
Next-generation sequencing (NGS) variant calling is foundational to interpreting chemogenomic screens, where accurately linking genetic perturbations to compound sensitivity is paramount.
Error-corrected next-generation sequencing (ecNGS) has revolutionized the direct evaluation of genome-wide mutations following exposure to mutagens, enabling high-resolution detection of chemical-induced genetic alterations.